INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)
· ·

Application Number		10575817		
Filing Date		2006-04-14		
First Named Inventor Ronal		ld Goodrich		
Art Unit				
Examiner Name				
Attorney Docket Number		018778-9207-01		

		Remove				
Examiner Initial*			Kind Code <sup>1</sup>			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6698998		2004-03-02	Koretsky	
2 6602041 2003-09-05 Levis et al. 3 6179645 2001-01-30 Petersen, Jr. et al.		Lewis et al.				
		6179545		2001-01-30	Petersen, Jr. et al.	
	4	5391041		1995-02-21	Stanbury et al.	
	5	4909700		1990-03-20	Fontecchio et al.	
	6	4450753		1984-05-29	Basrai et al.	
	7	4422474		1983-12-27	Basrai et al.	
If you wish	to a	dd additional U.S. Pat	ent citatio	n information p	lease click the Add button.	Add

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10575817
Filing Date		2006-04-14
First Named Inventor Ronal		id Goodrich
Art Unit		
Examiner Name		
Attorney Docket Number		018778-9207-01

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant Rele		Relev	ges,Columns,Lines where levant Passages or Relevant ures Appear		
	1	20020197141		2002-12	2-26	Cohn					
If you wis	n to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information	please click the Ad	d buttor	n. Add		
				FORE	GN PAT	TENT DOCUM	MENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	where Re	or Relevant	TS
	1	02/083455	wo			2002-10-24	LIFT-U, DIVISION HOGAN MGF., INC				
	2	02/26526	wo			2002-04-04	LIFT-U, DIVISION HOGAN MGF., INC				
	3	01/45625	wo			2001-06-28	LIFT-U, DIVISION HOGAN MGF., INC				
If you wis	n to a	dd additional Foreign F	atent Do	cument	citation	information p	lease click the Add	button			
			NON	I-PATE	NT LITE	ERATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner   Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book majorine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T5					
"Entervan Owner's/Service Manual for Fully Automatic 1996 Chrysler Entervan II", The Braun Corporation, January, 1996     "Shuttle Valve KO483" Technical Specification, Sterling Hydraulics.					n, January,						

#### 

EXAMINER SIGNATURE							
Examiner Signature		Date Considered					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a itation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

See Kint Codes of USPTO Patent Documents at sever USPTO GOV; or MPEP 901.04. Enter of tice that issued the document, by the two-letter of the Spandard ST3.) For Explaneses patent documents, the included on the year of the import on precise to the sent and replaned document of the Emporer name precise the sent and replaned document. If kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possible. Spoticant is to place a check mark here if English languages translation is statistical.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10575817
Filing Date		2006-04-14
First Named Inventor Ronal		id Goodrich
Art Unit		
Examiner Name		
Attorney Docket Number		018778-9207-01

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/martin I. stern/	Date (YYYY-MM-DD)	2007-04-16
Name/Print	Martin I. Stem	Registration Number	28911

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.